

Documents transmis le 16/03/2021 - Latanoprost

PUBLIÉ LE 20/05/2021 - MIS À JOUR LE 25/05/2021

AMM Vizilatan 50 microgrammes/ml, collyre en solution (2018)



Latanoprost - Braille (2018)



Latanoprost - Annexe 54 (2017)



Latanoprost - Manufacturer's authorisation (2017)



Latanoprost - Certificate of GMP compliance of a manufacturer



Latanoprost - Letter of access (2017)



Latanoprost - Letter of commitment (2017)



Latanoprost - Annexe 517 (2017)



Latanoprost - List of proposed (invented) names and marketing authorisation holders in the concerned member states (2017)



Latanoprost - Certificate of GMP compliance of a manufacturer



Latanoprost - Submission of Application Dossier(s) for Marketing Authorisation of Latanoprost 50 micrograms/mL PF eye drops solution (2017)



Latanoprost - Package leaflet: Information for the user (2017)



Latanoprost - Justification for Absence of Environmental Risk Assessment (2017)



Latanoprost - Product information (2017)



| | |
|--|---|
| Latanoprost - Labelling (2017) |  |
| Latanoprost - Exclu (2017) |  |
| Latanoprost - Information for generic, "hybrid" or bio-similar applications (2017) |  |
| Latanoprost - Notice to applicants (2015) |  |
| Latanoprost - Patent (2017) |  |
| Latanoprost - Risk management plan (2017) |  |
| Latanoprost - Summary of the Valeant group Pharmacovigilance System (2017) |  |
| Latanoprost - Summary of product characteristics (2017) |  |
| Latanoprost - Extrait Kbis (2017) |  |
| Latanoprost - Specimen (2017) |  |
| Latanoprost - Track (2017) |  |
| Latanoprost - Appendices (2017) |  |
| Latanoprost - Clinical overview (2017) |  |
| Latanoprost - Introduction (2017) |  |
| Latanoprost - Nonclinical summary (2017) |  |
| Latanoprost - Nonclinical overview (2017) |  |
| Latanoprost - Clinical summary (2017) |  |
| Latanoprost - Regional information / For EU (2017) |  |

